Selective Orexin Receptor Antagonists as Novel Augmentation Treatments for Major Depressive Disorder: Evidence for Safety and Efficacy From a Phase 2B Study of Seltorexant

There is a large unmet need for effective treatment of major depressive disorder (MDD), an often chronic/recurrent disorder that affects 1 in 5 adults during their lifetime in the United States. Clinicians and individuals with MDD often rely on augmentation approaches given the low rate of remission...

Descripción completa

Detalles Bibliográficos
Autor principal: Jha, Manish Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756081/
https://www.ncbi.nlm.nih.gov/pubmed/34791262
http://dx.doi.org/10.1093/ijnp/pyab078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756081/
https://www.ncbi.nlm.nih.gov/pubmed/34791262
http://dx.doi.org/10.1093/ijnp/pyab078

Ejemplares similares